Finance

Lists
1093:HKG
CSPC Pharmaceutical Group Ltd
HK$ 8.88
+0.17%
(+0.015) 1D
10-р сарын 16, 16:08:14 (GMT+8)  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1093...
Open
HK$ 9.09
High
HK$ 9.19
Low
HK$ 8.77
Mkt. cap
102.26Т
Avg. vol.
76.68 сая
Volume
72.90 сая
Dividend
3.72%
Quarterly dividend
HK$ 0.08
Ex-dividend date
2026 оны 10-р сарын 20
P/E ratio
11.64
52-wk high
HK$ 10.96
52-wk low
HK$ 6.53
EPS
HK$ 0.76
Shares outstanding
11.52 тэрбум
No. of employees
19 мян
Open
HK$ 9.09
High
HK$ 9.19
Low
HK$ 8.77
Mkt. cap
102.26Т
Avg. vol.
76.68 сая
Volume
72.90 сая
Dividend
3.72%
Quarterly dividend
HK$ 0.08
Ex-dividend date
2026 оны 10-р сарын 20
P/E ratio
11.64
52-wk high
HK$ 10.96
52-wk low
HK$ 6.53
EPS
HK$ 0.76
Shares outstanding
11.52 тэрбум
No. of employees
19 мян
News stories
From web sources and news partners
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's "500 Most Valuable Chinese Brands" and "Top 500 Chinese Enterprises." Wikipedia
About CSPC Pharmaceutical Group Ltd
CEOZhang Cuilong
Employees18.6 мян
Founded1992
Headquarters-
SectorPharmaceutical industry
Last report
2026 оны 8-р сарын 20
Fiscal period
Q2 2026
- / -
Revenue / Est. (HKD)
14.13 тэрбум / 10.11 тэрбум
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
6.62 тэрбум
6.11 тэрбум
6.47 тэрбум
12.13 тэрбум
Cost of goods sold
2.28 тэрбум
2.11 тэрбум
2.20 тэрбум
2.24 тэрбум
Cost of revenue
2.28 тэрбум
2.11 тэрбум
2.20 тэрбум
2.24 тэрбум
Research and development expenses
1.50 тэрбум
1.62 тэрбум
1.40 тэрбум
1.63 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.97 тэрбум
1.87 тэрбум
1.89 тэрбум
1.89 тэрбум
Operating expense
3.47 тэрбум
3.49 тэрбум
3.29 тэрбум
3.51 тэрбум
Total operating expenses
5.75 тэрбум
5.60 тэрбум
5.49 тэрбум
5.75 тэрбум
Operating income
869.63 сая
514.71 сая
973.82 сая
6.38 тэрбум
Other non operating income
645.14 сая
-470.42 сая
181.80 сая
11.92 сая
EBT including unusual items
1.18 тэрбум
505.59 сая
1.13 тэрбум
6.40 тэрбум
EBT excluding unusual items
1.37 тэрбум
186.56 сая
1.13 тэрбум
6.35 тэрбум
Income tax expense
222.47 сая
165.64 сая
243.25 сая
825.70 сая
Effective tax rate
18.78%
32.76%
21.46%
12.91%
Other operating expenses
-
-
-
-
Net income
963.54 сая
370.72 сая
859.79 сая
5.23 тэрбум
Net profit margin
14.56%
6.06%
13.30%
43.16%
Earnings per share
-
-
-
-
Interest and investment income
-
195.87 сая
-
91.68 сая
Interest expense
-104.94 сая
-6.76 сая
-11.01 сая
-2.30 сая
Net interest expenses
-104.94 сая
189.12 сая
-11.01 сая
89.37 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
1.14 тэрбум
802.06 сая
1.26 тэрбум
6.67 тэрбум
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс